Emily D Bethea1,2,3, Qiushi Chen1,2, Chin Hur1,2,3, Raymond T Chung2,3, Jagpreet Chhatwal1,2,3. 1. Massachusetts General Hospital Institute for Technology Assessment, Boston, MA. 2. Harvard Medical School, Boston, MA. 3. Liver Center and Gastrointestinal Division, Massachusetts General Hospital, Boston, MA.
Abstract
It is not standard practice to treat patients with acute hepatitis C virus (HCV) infection. However, as the incidence of HCV in the United States continues to rise, it may be time to re-evaluate acute HCV management in the era of direct-acting antiviral (DAA) agents. In this study, a microsimulation model was developed to analyze the trade-offs between initiating HCV therapy in the acute versus chronic phase of infection. By simulating the lifetime clinical course of patients with acute HCV infection, we were able to project long-term outcomes such as quality-adjusted life years (QALYs) and costs. We found that treating acute HCV versus deferring treatment until the chronic phase increased QALYs by 0.02 and increased costs by $483 in patients not at risk of transmitting HCV. The resulting incremental cost-effectiveness ratio was $19,991 per QALY, demonstrating that treatment of acute HCV was cost-effective using a willingness-to-pay threshold of $100,000 per QALY. In patients at risk of transmitting HCV, treating acute HCV became cost-saving, increasing QALYs by 0.03 and decreasing costs by $3,655. CONCLUSION: Immediate treatment of acute HCV with DAAs can improve clinical outcomes and be highly cost-effective or cost-saving compared with deferring treatment until the chronic phase of infection. If future studies continue to demonstrate effective HCV cure with shorter 6-week treatment duration, then it may be time to revisit current HCV guidelines to incorporate recommendations that account for the clinical and economic benefits of treating acute HCV in the era of DAAs. (Hepatology 2018;67:837-846).
It is not standard practice to treat patients with acute hepatitis C virus (HCV) infection. However, as the incidence of HCV in the United States continues to rise, it may be time to re-evaluate acute HCV management in the era of direct-acting antiviral (DAA) agents. In this study, a microsimulation model was developed to analyze the trade-offs between initiating HCV therapy in the acute versus chronic phase of infection. By simulating the lifetime clinical course of patients with acute HCV infection, we were able to project long-term outcomes such as quality-adjusted life years (QALYs) and costs. We found that treating acute HCV versus deferring treatment until the chronic phase increased QALYs by 0.02 and increased costs by $483 in patients not at risk of transmitting HCV. The resulting incremental cost-effectiveness ratio was $19,991 per QALY, demonstrating that treatment of acute HCV was cost-effective using a willingness-to-pay threshold of $100,000 per QALY. In patients at risk of transmitting HCV, treating acute HCV became cost-saving, increasing QALYs by 0.03 and decreasing costs by $3,655. CONCLUSION: Immediate treatment of acute HCV with DAAs can improve clinical outcomes and be highly cost-effective or cost-saving compared with deferring treatment until the chronic phase of infection. If future studies continue to demonstrate effective HCV cure with shorter 6-week treatment duration, then it may be time to revisit current HCV guidelines to incorporate recommendations that account for the clinical and economic benefits of treating acute HCV in the era of DAAs. (Hepatology 2018;67:837-846).
Authors: Jason Grebely; Kimberly Page; Rachel Sacks-Davis; Maarten Schim van der Loeff; Thomas M Rice; Julie Bruneau; Meghan D Morris; Behzad Hajarizadeh; Janaki Amin; Andrea L Cox; Arthur Y Kim; Barbara H McGovern; Janke Schinkel; Jacob George; Naglaa H Shoukry; Georg M Lauer; Lisa Maher; Andrew R Lloyd; Margaret Hellard; Gregory J Dore; Maria Prins Journal: Hepatology Date: 2013-11-22 Impact factor: 17.425
Authors: Carrie McAdam-Marx; Lisa J McGarry; Christopher A Hane; Joseph Biskupiak; Baris Deniz; Diana I Brixner Journal: J Manag Care Pharm Date: 2011-09
Authors: Kimberly Page; Judith A Hahn; Jennifer Evans; Stephen Shiboski; Paula Lum; Eric Delwart; Leslie Tobler; William Andrews; Lia Avanesyan; Stewart Cooper; Michael P Busch Journal: J Infect Dis Date: 2009-10-15 Impact factor: 5.226
Authors: Evan Gorstein; Marianne Martinello; Alexander Churkin; Swikriti Dasgupta; Kevin Walsh; Tanya L Applegate; David Yardeni; Ohad Etzion; Susan L Uprichard; Danny Barash; Scott J Cotler; Gail V Matthews; Harel Dahari Journal: Antiviral Res Date: 2020-06-25 Impact factor: 5.970
Authors: Eric Tatara; Nicholson T Collier; Jonathan Ozik; Alexander Gutfraind; Scott J Cotler; Harel Dahari; Marian Major; Basmattee Boodram Journal: Proc Winter Simul Conf Date: 2020-02-20
Authors: D A Axelrod; M A Schnitzler; T Alhamad; F Gordon; R D Bloom; G P Hess; H Xiao; M Nazzal; D L Segev; V R Dharnidharka; A S Naik; N N Lam; R Ouseph; B L Kasiske; C M Durand; K L Lentine Journal: Am J Transplant Date: 2018-05-29 Impact factor: 8.086
Authors: Lindsy Liu; Monika N Daftary; Mohammad S Alzahrani; Chiemena Ohanele; Mary K Maneno Journal: J Natl Med Assoc Date: 2020-08-28 Impact factor: 1.798